AsianScientist (Aug. 27, 2015) – Cellular Biomedicine Group Inc (CBMG), a biomedicine firm headquartered in China, has appointed of Dr. Yao Yihong as chief scientific officer (CSO). In this new position, Yao will spearhead the company’s overall scientific research programs in the areas of immuno-oncology and inflammatory/autoimmune diseases and will be responsible for strengthening the company’s immuno-oncology platforms and clinical trial design and bioinformatics.
“Yao brings to the company’s management team extensive working knowledge in translational medicine strategies as well as a scientific background that will support our research in both inflammatory/autoimmune and especially in the immuno-oncology fields,” said Dr. William Cao Wei, CEO of CBMG.
“His experience in clinical trial design and clinical bioinformatics will be a great asset as we prepare to advance clinical trials for the Company’s CD40LGVAX vaccine combination therapy for non-small cell lung cancer (NSCLC) and CAR-T assets in hematological and solid tumors.”
Yao has been credited for successfully building a dynamic pharmacogenomics team during his previous tenure with MedImmune and AstraZeneca. In particular, his experience in patient disease segmentation, clinical biomarkers and companion diagnostics development were cited as reasons for his appointment.
“I feel honored to have the opportunity to work with CBMG’s talented scientific research team to fulfill our mission to find new ways to develop and deliver innovative therapies for unmet medical needs in China, where 3.5 million new cancer patients are diagnosed each year,” said Yao.
“Together with the rest of the leadership team and all the employees of the Company, I am confident CBMG will make a social and economic impact towards deadly cancerous diseases as well as debilitating degenerative diseases.”
Dr. Yao received his bachelors degree in biochemistry from Fudan University, a master’s degree in bioinformatics from Boston University and his Ph.D. in molecular biology & biochemistry from the University of Kansas. He completed his postdoctoral fellowship at Johns Hopkins University before going on to attain over fifteen years of professional experience in companies including MedImmune, the biologics research and development arm of AstraZeneca, and Abbott Bioresearch Center.
———
Source: Cellular Biomedicine Group.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
